RxDoctor Payments Data

Rekha Reddy, MD

Internal Medicine · Longview, TXNPI 1285630558

Payments from drug & device makers

$1,594in general payments, 2019–2025

Across 107 payments — averaging $14.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$268
  • Novo Nordisk$247
  • Johnson & Johnson$181
  • Amgen$153
  • Boston Scientific$150
  • Smith+Nephew$117
  • plus $479 from 13 others

What the payments were for

  • Food & beverage$1,594100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,594 in reported general payments places this provider in the 75th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$116,180
Medicare patients
413
Services billed
1,415

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin131$184,579
OzempicSemaglutide82$132,982
TrulicityDulaglutide74$108,373
JanuviaSitagliptin Phosphate58$77,594
EliquisApixaban80$65,922
RybelsusSemaglutide37$54,978
XareltoRivaroxaban22$24,954
SymbicortBudesonide/Formoterol Fumarate62$19,862
MounjaroTirzepatide12$19,445
JanumetSitagliptin Phos/Metformin Hcl14$19,139
LinzessLinaclotide15$14,865
FarxigaDapagliflozin Propanediol14$14,646
Atorvastatin Calcium1,340$10,424
Gabapentin453$7,713
Potassium Chloride468$7,339

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$247$187,960119 claims
Boehringer IngelheimJardiance$58$184,579131 claims
Lilly USA, LLCTrulicity, Mounjaro$12$127,81986 claims
MerckJanuvia, Janumet$51$96,73472 claims
PfizerEliquis, Premarin$268$68,27891 claims
AstraZenecaSymbicort, Farxiga$98$34,50876 claims
Johnson & JohnsonXarelto$181$24,95422 claims
AbbVieLinzess$68$14,86515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Longview

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →